Patterns of failure in cases of carcinoma of esophagus treated with radical concurrent chemoradiation
Abstract
Background: Radical chemoradiation has been the main stay of treatment in inoperable cases of carcinoma of thoracic oesophagus. The purpose of the study is to determine the pattern of recurrence after radical concurrent chemoradiation.
Materials and Methods: Fifty patients with carcinoma esophagus treated with chemoradiation were taken retrospectively for this study. All the patients were treated with external beam radiation therapy (3DCRT/IMRT) of 54 to 59.4Gy with 3 weekly cisplatin 80 mg/m2 and capicitabine 1250 mg /m2. All patients were followed with upper GI endoscopy at 3-4 monthly for first 3 years, CECT thorax and abdomen at every 3 month for 1 year then 6 monthly up to 3 year thereafter yearly follow up. Appropriate statistics were used for the analysis. All the patient information was taken out from the case files and by telephonic interview.
Results: 50 patients were included in the retrospective analysis. Median age was 54 years. 26 (52%) were males and 24(48%) were females. Most common tumour histology being squamous cell carcinoma and most common site being the middle 1/3 of esophagus 30/50(60%). 47/50 (94%) patients received concurrent chemoradiation with cisplatin with capecitabine and 3/50 (6%) received induction chemotherapy with cisplatin and 5-FU. Patients were followed up for a period of 8 months to 34 months (median: 21 months). At the time of last follow up in September 2015, 23/50(46%) patients had local recurrence, 14 (28%) patients had distant failure and 13(26%) patients had no evidence of disease at the time of last follow up. With a median follow up of 21 months, mean overall survival for all the patients was 17.5 months. Patients surviving at the end of 1 year were 68%, at 2 years was 36%, and at 3 years was 4.3%.
Conclusion: This study concludes that highest incidence of failure and recurrences occur most commonly locally (within the previously irradiated field) even after definitive radical treatment with concurrent chemoradiation. As the local recurrence is more than distant failure we should aim at consolidating the local therapy by dose escalation or alternative radiation therapy.
Downloads
References
2. Kelsen DP, Winter KA, Gunderson LL, et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007; 25(24):3719–25.
3. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997; 337(3):161–7.
4. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996; 335(7):462– 7.
5. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008; 26(7):1086–92.
6. Forastiere AA. Treatment of locoregional esophageal cancer. Semin Oncol. 1992; 19(4 Suppl 11): 57–63
7. Herscher LL, Cook JA, Pacelli R, Pass HI, Russo A, Mitchell JB. Principles of chemoradiation: theoretical and practical considerations. Oncology (Williston Park). 1999; 13(10 Suppl 5):11–22. [
8. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standarddose radiation therapy. J Clin Oncol. 2002; 20(5):1167–74.
9. Minsky BD, Pajak TF, Ginsberg RJ. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002; 20:1167–74.
10. Zhu XR, Sahoo N, Zhang X, et al. Intensity modulated proton therapy treatment planning using single-field optimization: the impact of monitor unit constraints on plan quality. Med Phys. 2010 Mar;37(3):1210-9.
11. Welsh J, Palmer MB, Ajani JA, et al. Esophageal Cancer Dose Escalation using a Simultaneous Integrated Boost Technique. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):468-74. doi: 10.1016/j.ijrobp.2010.10.023. Epub 2010 Dec 1.
12. Welsh J, Riley B, Palmera M, et al. Intensity Modulated Proton Therapy Allows Dose Escalation and Normal-Tissue Sparing in Locally Advanced Distal Esophageal Tumors. Curr Oncol Rep. 2011 Jun; 13(3): 157–167. doi: 10.1007/s11912-011-0158-z
13. Shukovsky LJ, Fletcher GH. Time-dose and tumor volume relationships in the irradiation of squamous cell carcinoma of the tonsillar fossa. Radiology. 1973; 107(3):621–6.
14. Minsky BD, Pajak TF, Ginsberg RJ. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002; 20:1167–74.
15. Marks LB, Zeng J, Light K, Kahn D, Zhou S. 116: Radiation-Induced Esophageal Stricture Following Therapy for Lung Cancer: Its Clinical Course and Analysis Comparing Stricture Length With Isodose Levels. International Journal of Radiation Oncology*Biology*Physics. 2006;66(3, Supplement 1):S66–S67.
OAI - Open Archives Initiative
